Thymosin α1 Combined with PD-1/PD-L1 Inhibitor Plus Chemotherapy in Platinum-Resistant Recurrent Ovarian Cancer : A Retrospective Analysis
The addition of Tα1 to PD-1/PD-L1 inhibitor-based chemotherapy may enhance treatment efficacy, improve immune response, and reduce immunosuppression-related toxicity in patients with platinum-resistant recurrent ovarian cancer.
Authors
- Zhendong Li (ORCID: https://orcid.org/0000-0002-3930-2888)
- Lixia Wang (ORCID: https://orcid.org/0000-0003-1338-9126)
- Hao Zhong (ORCID: https://orcid.org/0000-0003-0537-8582)
- Hong Wang (ORCID: https://orcid.org/0000-0002-4879-4482)
Institutions
- Neijiang Normal University (CN)
Publication Details
- Journal
- Cancer Management and Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/cmar.s542744
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Sichuan Province